Cyclo-oxygenase (COX) inhibitors are associated with increased cardiovascular risk, and are, therefore, contraindicated in patients with a previous myocardial infarction (MI). Although NSAIDs might induce a similar cardiovascular risk, some guidelines suggest that they can be administered safely for a short period of time. But is this really true?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
European Medicines Agency. Press release 24 October 2006. European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAID's [online], (2006).
Antman, E. M. et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115, 1634–1642 (2007).
Schjerning Olsen, A. M. et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123, 2226–2235 (2011).
Nurmohamed, M. T. Cardiovascular risk in rheumatoid arthritis. Autoimmun. Rev. 8, 663–667 (2009).
Kearney, P. M. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332, 1302–1308 (2006).
Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S. & Libby, P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol. 155, 1281–1291 (1999).
Sørensen, R. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374, 1967–1974 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Michael T. Nurmohamed has acted as a consultant and received speakers bureau/honoraria and grant/research support from Abbott, Bristol–Myers Squibb, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Schering–Plough, UCB and Wyeth.
Rights and permissions
About this article
Cite this article
Nurmohamed, M. Are NSAIDs safe to use in post-MI patients?. Nat Rev Rheumatol 7, 561–562 (2011). https://doi.org/10.1038/nrrheum.2011.116
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2011.116
